by Carrie Strehlau
About 10 percent of young leukemia patients of East Asian ancestry inherit a gene variation that is associated with reduced tolerance of a drug that is indispensable for curing acute lymphoblastic leukemia (ALL), the most common childhood cancer. St. Jude Children's Research Hospital scientists led the study, which is being published online today in the Journal of Clinical Oncology.
Researchers reported that patients who inherited either one or two copies of the newly identified variation in the NUDT15 gene were extremely sensitive to the drug mercaptopurine. Patients with the NUDT15 variant required a mercaptopurine dose reduction of as much as 92 percent. At standard doses patients developed side effects that caused treatment delays and threatened their chances of cures.
The finding should aid efforts to improve identification and treatment of patients who need reduced doses of mercaptopurine. Mercaptopurine is the backbone of chemotherapy that has helped transform the outlook for young ALL patients. At St. Jude, 94 percent of newly diagnosed ALL patients now become long-term survivors.
In this study, patients of East Asian and Hispanic background were more likely to inherit the NUDT15 variant than those from other racial and ethnic groups. Among patients of East Asian ancestry, 9.8 percent carried at least one copy of the NUDT15 variant, compared to 3.9 percent of Hispanic patients. The variant was rarer among those of European or African ancestry. East Asia includes China, Japan and Korea.
"Mercaptopurine intolerance has been suspected to be a problem for young ALL patients of East Asian ancestry. Even at very low doses, the patients often develop toxicity that delays treatment, but until now the genetic basis of the problem was unknown," said Jun J. Yang, Ph.D., an assistant member of the St. Jude Department of Pharmaceutical Sciences. Yang is first and corresponding author of the paper.
St. Jude is a pioneer in the field of pharmacogenetics, which focuses on how inherited differences in the makeup of genes influence patients' drug responses. This study confirmed previous St. Jude research that showed variations in another gene, TPMT, were also associated with an increased risk of mercaptopurine toxicity. St. Jude patients are now routinely tested for the TPMT variants, and the results help determine the mercaptopurine dose patients receive.
The TPMT variants did not completely explain mercaptopurine toxicity. The TPMT variants are less common in individuals of East Asian ancestry. TPMT carries instructions for a protein of the same name. Some patients with normal TPMT still cannot tolerate standard doses of the drug. "That suggested there are other inherited genetic risk factors at play," Yang said.
This study is the most comprehensive effort yet to identify the genetic basis of mercaptopurine intolerance in young ALL patients. Researchers screened the DNA of 657 pediatric ALL patients for 40,889 different inherited genetic variations. The patients were enrolled in a Children's Oncology Group (COG) clinical trial. COG is a federally supported clinical trials network focused exclusively on childhood cancer research. Patients were scheduled to receive standard daily doses of mercaptopurine. The doses were reduced, however, if patients developed infections or other drug-related complications.
Patients who inherited variations in TPMT or NUDT15 tolerated mercaptopurine at significantly lower doses than patients who inherited the more common versions of the genes. Investigators checked 371 young ALL patients enrolled in a separate St. Jude clinical trial and confirmed the association. The same NUDT15 variation has also been linked to mercaptopurine toxicity in Korean patients with inflammatory bowel disease.
TPMT carries instructions for assembling an enzyme of the same name that inactivates mercaptopurine and related drugs. The TPMT variants are less able to inactivate the drug, which can lead to a dangerous build-up of mercaptopurine and suppression of the immune system. Researchers suspect that the NUDT15 variant acts in a similar fashion. "The results of this study confirm that TPMT genetic variation is one of the most critical determinants of mercaptopurine tolerance, particularly in non-East Asian populations," said senior author Mary Relling, Pharm.D., chair of the St. Jude Department of Pharmaceutical Sciences. "But we also found that TPMT variants do not completely explain mercaptopurine intolerance, particularly in patients of East Asian ancestry."
Six percent of the patients in this study who required more than a 50 percent reduction in mercaptopurine inherited neither the TPMT nor NUDT15 variants. "Other factors, both genetic and non-genetic, are still to be discovered to improve the safety and effective of mercaptopurine treatment for children with ALL," Relling said.
Explore further: Good news for young patients with a leukemia subtype associated with a poor prognosis
Medical Xpress on facebook
Related Stories
Inherited gene variation tied to high-risk pediatric leukemia and greater risk of relapse
Oct 20, 2013
Research led by St. Jude Children's Research Hospital scientists has linked an inherited gene variation to a nearly four-fold increased risk of developing a pediatric acute lymphoblastic leukemia (ALL) subtype ...
Inherited risk factors for childhood leukemia are more common in Hispanic patients
Jan 30, 2012
Hispanic children are more likely than those from other racial and ethnic backgrounds to be diagnosed with acute lymphoblastic leukemia (ALL) and are more likely to die of their disease. Work led by St. Jude Children's Research ...
Inherited genetic variations have a major impact on childhood leukemia risk
Mar 19, 2013
Humans have between 20,000 and 25,000 genes that carry instructions for assembling the proteins that do the work of cells. Work led by St. Jude Children's Research Hospital found that children who inherit certain variations ...
Newly identified DNA repair defect linked to increased risk of leukemia relapse
Sep 26, 2011
A newly identified defect in a DNA repair system might leave some young leukemia patients less likely to benefit from a key chemotherapy drug, possibly putting them at greater risk of relapse. The problem was identified in ...
Native American ancestry linked to greater risk of relapse in young leukemia patients
Feb 06, 2011
The first genome-wide study to demonstrate an inherited genetic basis for racial and ethnic disparities in cancer survival linked Native American ancestry with an increased risk of relapse in young leukemia patients. The ...
Recommended for you
Inhibiting CDK6 prevents leukemic relapse
23 minutes ago
Despite enormous progress in cancer therapy, many patients still relapse because their treatment addresses the symptoms of the disease rather than the cause, the so-called stem cells. Work in the group of ...
Metabolic process of the liver implicated in the spread of colorectal cancer
1 hour ago
Colorectal cancer is a cancer on the move: about 50 percent of patients with the disease see their cancer spread, typically to the liver. By identifying genes that become activated in cancer cells that successfully travel—metastasize—to ...
Smoking may increase risks for patients being treated for prostate cancer
8 hours ago
Among patients with prostate cancer, those who smoke have increased risks of experiencing side effects from treatment and of developing future cancer recurrences, or even dying from prostate cancer. The findings, which are ...
Death rates from lung cancer will overtake those for breast cancer in 2015 among EU women
13 hours ago
Death rates from lung cancer will exceed those for breast cancer for the first time among European women in 2015, according to the latest predictions published in the leading cancer journal Annals of Oncology today.
Protein-based therapy shows promise against resistant leukemia
15 hours ago
Resistance of leukemia cells to contemporary chemotherapy is one of the most formidable obstacles to treating acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Now researchers ...
New model better predicts breast cancer risk in African American women
15 hours ago
Researchers from Boston University's Slone Epidemiology Center have developed a breast cancer risk prediction model for African- American women that found greater accuracy in predicting risk for the disease. The use of this ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
by Carrie Strehlau
About 10 percent of young leukemia patients of East Asian ancestry inherit a gene variation that is associated with reduced tolerance of a drug that is indispensable for curing acute lymphoblastic leukemia (ALL), the most common childhood cancer. St. Jude Children's Research Hospital scientists led the study, which is being published online today in the Journal of Clinical Oncology.
Researchers reported that patients who inherited either one or two copies of the newly identified variation in the NUDT15 gene were extremely sensitive to the drug mercaptopurine. Patients with the NUDT15 variant required a mercaptopurine dose reduction of as much as 92 percent. At standard doses patients developed side effects that caused treatment delays and threatened their chances of cures.
The finding should aid efforts to improve identification and treatment of patients who need reduced doses of mercaptopurine. Mercaptopurine is the backbone of chemotherapy that has helped transform the outlook for young ALL patients. At St. Jude, 94 percent of newly diagnosed ALL patients now become long-term survivors.
In this study, patients of East Asian and Hispanic background were more likely to inherit the NUDT15 variant than those from other racial and ethnic groups. Among patients of East Asian ancestry, 9.8 percent carried at least one copy of the NUDT15 variant, compared to 3.9 percent of Hispanic patients. The variant was rarer among those of European or African ancestry. East Asia includes China, Japan and Korea.
"Mercaptopurine intolerance has been suspected to be a problem for young ALL patients of East Asian ancestry. Even at very low doses, the patients often develop toxicity that delays treatment, but until now the genetic basis of the problem was unknown," said Jun J. Yang, Ph.D., an assistant member of the St. Jude Department of Pharmaceutical Sciences. Yang is first and corresponding author of the paper.
St. Jude is a pioneer in the field of pharmacogenetics, which focuses on how inherited differences in the makeup of genes influence patients' drug responses. This study confirmed previous St. Jude research that showed variations in another gene, TPMT, were also associated with an increased risk of mercaptopurine toxicity. St. Jude patients are now routinely tested for the TPMT variants, and the results help determine the mercaptopurine dose patients receive.
The TPMT variants did not completely explain mercaptopurine toxicity. The TPMT variants are less common in individuals of East Asian ancestry. TPMT carries instructions for a protein of the same name. Some patients with normal TPMT still cannot tolerate standard doses of the drug. "That suggested there are other inherited genetic risk factors at play," Yang said.
This study is the most comprehensive effort yet to identify the genetic basis of mercaptopurine intolerance in young ALL patients. Researchers screened the DNA of 657 pediatric ALL patients for 40,889 different inherited genetic variations. The patients were enrolled in a Children's Oncology Group (COG) clinical trial. COG is a federally supported clinical trials network focused exclusively on childhood cancer research. Patients were scheduled to receive standard daily doses of mercaptopurine. The doses were reduced, however, if patients developed infections or other drug-related complications.
Patients who inherited variations in TPMT or NUDT15 tolerated mercaptopurine at significantly lower doses than patients who inherited the more common versions of the genes. Investigators checked 371 young ALL patients enrolled in a separate St. Jude clinical trial and confirmed the association. The same NUDT15 variation has also been linked to mercaptopurine toxicity in Korean patients with inflammatory bowel disease.
TPMT carries instructions for assembling an enzyme of the same name that inactivates mercaptopurine and related drugs. The TPMT variants are less able to inactivate the drug, which can lead to a dangerous build-up of mercaptopurine and suppression of the immune system. Researchers suspect that the NUDT15 variant acts in a similar fashion. "The results of this study confirm that TPMT genetic variation is one of the most critical determinants of mercaptopurine tolerance, particularly in non-East Asian populations," said senior author Mary Relling, Pharm.D., chair of the St. Jude Department of Pharmaceutical Sciences. "But we also found that TPMT variants do not completely explain mercaptopurine intolerance, particularly in patients of East Asian ancestry."
Six percent of the patients in this study who required more than a 50 percent reduction in mercaptopurine inherited neither the TPMT nor NUDT15 variants. "Other factors, both genetic and non-genetic, are still to be discovered to improve the safety and effective of mercaptopurine treatment for children with ALL," Relling said.
Explore further: Good news for young patients with a leukemia subtype associated with a poor prognosis
Medical Xpress on facebook
Related Stories
Inherited gene variation tied to high-risk pediatric leukemia and greater risk of relapse
Oct 20, 2013
Research led by St. Jude Children's Research Hospital scientists has linked an inherited gene variation to a nearly four-fold increased risk of developing a pediatric acute lymphoblastic leukemia (ALL) subtype ...
Inherited risk factors for childhood leukemia are more common in Hispanic patients
Jan 30, 2012
Hispanic children are more likely than those from other racial and ethnic backgrounds to be diagnosed with acute lymphoblastic leukemia (ALL) and are more likely to die of their disease. Work led by St. Jude Children's Research ...
Inherited genetic variations have a major impact on childhood leukemia risk
Mar 19, 2013
Humans have between 20,000 and 25,000 genes that carry instructions for assembling the proteins that do the work of cells. Work led by St. Jude Children's Research Hospital found that children who inherit certain variations ...
Newly identified DNA repair defect linked to increased risk of leukemia relapse
Sep 26, 2011
A newly identified defect in a DNA repair system might leave some young leukemia patients less likely to benefit from a key chemotherapy drug, possibly putting them at greater risk of relapse. The problem was identified in ...
Native American ancestry linked to greater risk of relapse in young leukemia patients
Feb 06, 2011
The first genome-wide study to demonstrate an inherited genetic basis for racial and ethnic disparities in cancer survival linked Native American ancestry with an increased risk of relapse in young leukemia patients. The ...
Recommended for you
Inhibiting CDK6 prevents leukemic relapse
23 minutes ago
Despite enormous progress in cancer therapy, many patients still relapse because their treatment addresses the symptoms of the disease rather than the cause, the so-called stem cells. Work in the group of ...
Metabolic process of the liver implicated in the spread of colorectal cancer
1 hour ago
Colorectal cancer is a cancer on the move: about 50 percent of patients with the disease see their cancer spread, typically to the liver. By identifying genes that become activated in cancer cells that successfully travel—metastasize—to ...
Smoking may increase risks for patients being treated for prostate cancer
8 hours ago
Among patients with prostate cancer, those who smoke have increased risks of experiencing side effects from treatment and of developing future cancer recurrences, or even dying from prostate cancer. The findings, which are ...
Death rates from lung cancer will overtake those for breast cancer in 2015 among EU women
13 hours ago
Death rates from lung cancer will exceed those for breast cancer for the first time among European women in 2015, according to the latest predictions published in the leading cancer journal Annals of Oncology today.
Protein-based therapy shows promise against resistant leukemia
15 hours ago
Resistance of leukemia cells to contemporary chemotherapy is one of the most formidable obstacles to treating acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Now researchers ...
New model better predicts breast cancer risk in African American women
15 hours ago
Researchers from Boston University's Slone Epidemiology Center have developed a breast cancer risk prediction model for African- American women that found greater accuracy in predicting risk for the disease. The use of this ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment